Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900 and Parvysmelanotide (VLRX001), both alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone to produce cortisol and enables the combat of stress and regulation of immune responses, maintenance of blood pressure, moderation of blood sugar, and regulation of metabolism. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
| 9.43 | |
| 9.43 | |
| - | |
| 9.43 | |
| 9.43 | |
| 8.42-12.06 | |
| 497 M | |
| 20.0638 | |
| 50 078 K | |
| 88 178 K | |
| 0.921 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Key Insights Clinuvel Pharmaceuticals' significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public 39% of the business is held by the ...
Clinuvel Pharmaceuticals (ASX:CUV) has had a rough three months with its share price down 16%. However, a closer look at its sound financials might cause you to think again. Given that fundamentals us...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
